PHARMACEUTICAL 2014

Nektar Therapeutics
Rank 181 of 234



PHARMACEUTICAL 2014

Nektar Therapeutics
Rank 181 of 234

The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 5.4% points.The greatest weakness of Nektar Therapeutics is the variable Other Liabilities, reducing the Economic Capital Ratio by 106% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 108% points below the market average of 243%.

Input Variable	Value in 1000 USD
Assets, Current	257,882
Cost of Goods Sold	0
Intangible Assets	76,501
Liabilities, Current	98,221
Liabilities, Non-Current	19,256
Other Assets	33,170
Other Compr. Net Income	0
Other Expenses	40,754
Other Liabilities	406,953
Other Net Income	-39,638
Other Revenues	148,921
Property and Equipment	66,974
Research and Development	190,010
Selling, General and Administrative Expense	40,532

Output Variable	Value in 1000 USD
Assets	434,527
Liabilities	524,430
Expenses	271,296
Revenues	148,921
Stockholders Equity	-89,903
Net Income	-162,013
Comprehensive Net Income	-162,013
BaseVar	709,406
ECR before LimitedLiability	-75%
Economic Capital Ratio	135%